News | January 03, 2026
Cupid reports record Q3, eyes GCC expansion with Saudi FMCG facility
Cupid is strengthening its footprint in the GCC region, focusing on supply responsiveness and market proximity
Cupid is strengthening its footprint in the GCC region, focusing on supply responsiveness and market proximity
It performs white blood cell differential counts and quantifies red blood cell and platelet morphology,
The acquisition adds HLD-0915, a once-daily oral therapy for prostate cancer, to Johnson & Johnson’s nearly 20-year legacy of innovation in the disease
Under his leadership, Chidamide became China’s first original small-molecule anti-tumor innovative drug and the country’s first pharmaceutical product globally licensed out
Transcenta will grant EirGenix a non-exclusive license to its Highly Intensified Continuous Bioprocessing (HiCB) platform
The study met its primary endpoint with flying colors
The partnership also sets the stage for broader collaboration on rare disease treatments
Harbour BioMed brings advanced antibody discovery platforms to the table
Lucid-MS represents a potential breakthrough in the treatment of multiple sclerosis
The company views ESG reporting as a strategic tool to build trust with clients, investors, regulators, and stakeholders worldwide
Subscribe To Our Newsletter & Stay Updated
